Blood pressure control is one of the most modifiable levers in cardiovascular longevity, yet a persistent gap exists between what evidence recommends and what physicians prescribe. That gap appears to be widening in a counterintuitive direction — away from a simpler, more effective approach that could meaningfully reduce stroke and heart attack risk for millions of adults.
A study published in the Journal of the American College of Cardiology examined prescription trends for single-pill combination (SPC) therapy — fixed-dose combinations of two or more antihypertensive agents in one tablet — among hypertensive patients. The analysis found that SPC use has not only remained low but has actually declined over the observed period. This is despite guidelines from major cardiology bodies endorsing combination therapy as a first- or early-line strategy for patients who are unlikely to reach blood pressure targets on monotherapy alone, which represents a substantial portion of the hypertensive population.
This finding sits in uncomfortable tension with a robust body of evidence. Meta-analyses consistently show that SPC regimens improve medication adherence by 20–30% compared to equivalent multi-pill regimens, and adherence is the single largest predictor of real-world blood pressure control. Fixed-dose combinations also reduce clinical inertia — the tendency for clinicians to delay intensifying therapy. The downward trend in SPC prescribing likely reflects a confluence of factors: physician habit, formulary restrictions, cost concerns, and generic availability skewing toward individual agents. The limitation here is that without patient-level adherence or outcome data, it is difficult to determine whether declining SPC use is translating into measurably worse blood pressure control at the population level. Still, this is a confirmatory signal reinforcing a well-documented implementation failure — the kind that costs lives quietly, without a single dramatic event.